Among the SSRIs, escitalopram was significantly associated with reduced clinical deterioration in COVID-19 patients, although other SSRIs (i.e., fluoxetine, sertraline, and paroxetine) did not reach statistical significance [ 62 ].
← all excerpts
Overview of the potential use of fluvoxamine for COVID-19 and long COVID.
1
—
—